Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 21,267 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.96.
Beigene Price Performance
NASDAQ:ONC opened at $255.37 on Friday. The company has a market cap of $24.99 billion, a price-to-earnings ratio of -30.99, a PEG ratio of 9.44 and a beta of 0.63. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $260.98. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.
Beigene Company Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Read More
- Five stocks we like better than Beigene
- Top Stocks Investing in 5G Technology
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- 3 Healthcare Dividend Stocks to Buy
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
